Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial by van Laar, JM et al.
Copyright 2014 American Medical Association. All rights reserved.
Autologous Hematopoietic Stem Cell Transplantation vs
Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous
Systemic Sclerosis
A Randomized Clinical Trial
JacobM. van Laar, MD, PhD; Dominique Farge, MD, PhD; Jacob K. Sont, PhD; Kamran Naraghi, MD; Zora Marjanovic, MD; Jérôme Larghero, PharMD, PhD;
Annemie J. Schuerwegh, MD, PhD; Erik W. A. Marijt, MD, PhD; Madelon C. Vonk, MD, PhD; Anton V. Schattenberg, MD, PhD;
MarcoMatucci-Cerinic, MD, PhD; Alexandre E. Voskuyl, MD, PhD; Arjan A. van de Loosdrecht, MD, PhD; Thomas Daikeler, MD; Ina Kötter, MD, PhD;
Marc Schmalzing, MD; Thierry Martin, MD, PhD; Bruno Lioure, MD; StefanM.Weiner, MD; Alexander Kreuter, MD; Christophe Deligny, MD;
Jean-Marc Durand, MD, PhD; Paul Emery, MD; Klaus P. Machold, MD; Francoise Sarrot-Reynauld, MD, PhD; KlausWarnatz, MD; Daniel F. P. Adoue, MD;
Joël Constans, MD; Hans-Peter Tony, MD; Nicoletta Del Papa, MD, PhD; Athanasios Fassas, MD; Andrea Himsel, MD; David Launay, MD, PhD;
Andrea LoMonaco, MD, PhD; Pierre Philippe, MD; Isabelle Quéré, MD, PhD; Éric Rich, MD; ReneWesthovens, MD, PhD; Bridget Griffiths, MD;
Riccardo Saccardi, MD; Frank H. van den Hoogen, MD, PhD;Willem E. Fibbe, MD, PhD; Gérard Socié, MD, PhD; Alois Gratwohl, MD; Alan Tyndall, MD;
for the EBMT/EULAR Scleroderma Study Group
IMPORTANCE High-dose immunosuppressive therapy and autologous hematopoietic stem
cell transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small
phase 2 trials.
OBJECTIVE To compare efficacy and safety of HSCT vs 12 successive monthly intravenous
pulses of cyclophosphamide.
DESIGN, SETTING, AND PARTICIPANTS The Autologous StemCell Transplantation International
Scleroderma (ASTIS) trial, a phase 3, multicenter, randomized (1:1), open-label, parallel-group,
clinical trial conducted in 10 countries at 29 centers with access to a European Group for
Blood andMarrow Transplantation–registered transplant facility. FromMarch 2001 to
October 2009, 156 patients with early diffuse cutaneous systemic sclerosis were recruited
and followed up until October 31, 2013.
INTERVENTIONS HSCT vs intravenous pulse cyclophosphamide.
MAIN OUTCOMES ANDMEASURES The primary end point was event-free survival, defined as
time from randomization until the occurrence of death or persistent major organ failure.
RESULTS A total of 156 patients were randomly assigned to receive HSCT (n = 79) or
cyclophosphamide (n = 77). During a median follow-up of 5.8 years, 53 events occurred: 22 in
the HSCT group (19 deaths and 3 irreversible organ failures) and 31 in the control group (23
deaths and 8 irreversible organ failures). During the first year, there were more events in the
HSCT group (13 events [16.5%], including 8 treatment-related deaths) than in the control
group (8 events [10.4%], with no treatment-related deaths). At 2 years, 14 events (17.7%) had
occurred cumulatively in the HSCT group vs 14 events (18.2%) in the control group; at 4 years,
15 events (19%) had occurred cumulatively in the HSCT group vs 20 events (26%) in the
control group. Time-varying hazard ratios (modeled with treatment × time interaction) for
event-free survival were 0.35 (95% CI, 0.16-0.74) at 2 years and 0.34 (95% CI, 0.16-0.74)
at 4 years.
CONCLUSIONS AND RELEVANCE Among patients with early diffuse cutaneous systemic
sclerosis, HSCT was associated with increased treatment-relatedmortality in the first year
after treatment. However, HCST conferred a significant long-term event-free survival benefit.
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S ystemic sclerosis is a heterogeneous autoimmune con-nective tissuediseasecharacterizedbyvasculopathy,au-toantibody formation, low-grade inflammation, and fi-
brosis in skin and internal organs, with varying geographical
prevalence (50-300 per million persons per year) and inci-
dence (2.3-22.8permillionpersonsper year).1,2 Previous stud-
ies have shown that systemic sclerosis is amenable to treat-
mentwithautologoushematopoietic stemcell transplantation
(HSCT).3-9 Improvement of skin involvement and functional
ability was consistently observed, although some studies
showed that HSCT can also ameliorate vasculopathy, im-
prove skin and lung involvement, and correct immune
abnormalities.10-13 The benefits of HSCT must be weighed
against the risk of serious toxicities due to organ involvement
in systemic sclerosis.14 It is still unclear whether HSCT pro-
longs survival in systemic sclerosis. We therefore conducted
a randomized clinical trial calledASTIS (Autologous StemCell
Transplantation International Scleroderma) to compare safety
and efficacy of HSCT vs 12 successive monthly intravenous
pulses of cyclophosphamide.
Methods
Study Design and Participants
TheASTIStrialwasaninvestigator-initiated, randomized,open-
label,parallel-grouptrial conducted in10countriesat29centers
with access to a European Group for Blood and Marrow
Transplantation–registeredtransplantfacility.15Patientswereeli-
gible if theywerebetween18and65yearsofage;haddiffusecu-
taneous systemic sclerosis according toAmericanRheumatism
Associationcriteria,16withmaximumdiseasedurationof4years;
minimummodifiedRodnanskinscore (mRSS)of 15 (range,0-51,
withhigher scores indicatingmoresevere skin thickening); and
involvementofheart, lungs,orkidneys(eAppendixintheSupple-
ment).Prior treatmentwithcyclophosphamidewasallowedup
to a cumulativedose of 5 g intravenously or up to 2mg/kgbody
weightorally for 3months.Patientswithseveremajororgan in-
volvement including severe pulmonary arterial hypertension
(PAH) (meanpulmonaryarterypressure>50mmHg)or serious
comorbiditieswereexcluded.Theprotocolwasamendedin2004
toallow inclusionofpatientswithdiseasedurationof 2yearsor
lessandnomajororgandysfunctionasdefinedabove,provided
they had anmRSS of at least 20 and an erythrocyte sedimenta-
tionrategreater than25mminthe firsthourand/orhemoglobin
lessthan11g/dLnotexplainedbycausesotherthanactivesclero-
derma.Theprotocolwasfurtheramendedin2008tomakeitcom-
pliant with the European Union Directive for Clinical Trials, to
change thepower calculationbecauseof a lower thanexpected
accrualandeventrate,andtoincludeguidanceonmonitoringand
treatment of Epstein-Barr virus (EBV) reactivation afterHSCT.
Ethical Approval
The study protocol was approved by the institutional review
board at each site and compliedwith country-specific regula-
tory requirements. The study was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice
guidelines. All patients provided written informed consent.
Randomization
After registration, patientswere randomly assigned in a 1:1 ra-
tio by blocked randomization to receive HSCT or 12 intrave-
nous pulses of cyclophosphamide (Figure 1). Block random-
ization was performed centrally by telephone at the study
administrationoffice according to a computer-generated ran-
domizationprogram for each site,with randomblock sizes (2,
4, 6). Treatment was allocated within blocks according to an
optimumassignmentprocedure (minimization) tobalance the
investigational and standard treatment groups for age (≤40
years, >40 years) and disease duration (<2 years, ≥2 years) but
includeda25%chance tobeassigned to thenonoptimal group.
Procedures
TheprotocolforHSCTwasdesignedwiththeintentiontoachieve
intensive lymphocyteablation.Peripheralbloodhematopoietic
stemcellsweremobilizedwith intravenouscyclophosphamide
(a total of 4 g/m2 administered in equal amounts on 2 consecu-
tive days) and filgrastim (10 μg/kg per day), harvested by leu-
kapheresis,andenrichedforCD34+cellsusingimmunomagnetic
separation (CliniMACS,MiltenyiBiotec).Theconditioning regi-
menconsistedof intravenouscyclophosphamide (a totalof 200
mg/kg intravenouslyover4consecutivedays) and intravenous
rabbit antithymocyte globulin (rbATG,Genzyme) (a total of 7.5
mg/kgadministered inequal amountsover 3 consecutivedays)
administeredwith intravenousmethylprednisolone (1mg/kg)
andhyperhydration, followedbyreinfusionofperipheralblood
autologous CD34+ stem cells (≥2 × 106/kg). Patients in the con-
trolgroupreceived12monthlypulsesof intravenouscyclophos-
phamide (750mg/m2). Crossingoverwasallowedafter the sec-
ondyear.Concomitantmedicationsorothertreatmentsdeemed
Figure 1. Flow of ASTIS (Autologous Stem Cell Transplantation
International Scleroderma) Trial
156 Patients randomized
79 Included in primary analysis 77 Included in primary analysis
79 Randomized to receive HSCT
75 Received HSCT as randomized
4 Did not receive HSCT
2 Major protocol violationa
1 Nonadherent
1 Withdrew consent
77 Randomized to receive
cyclophosphamide (control)
75 Received cyclophosphamide
as randomized
2 Did not receive
cyclophosphamide
1 Died
1 Nonadherent
71 Completed intervention
4 Discontinued intervention
3 Died
1 Adverse event
57 Completed intervention
18 Discontinued intervention
8 Nonadherent
4 Died
4 Adverse event
1 Major organ failure
1 Major protocol violationb
Information on the number of individuals screened and excluded was not
available for all centers. Twenty-two patients receiving hematopoietic stem cell
transplantation and 31 receiving cyclophosphamide (control group)
experienced 1 event (death or persistent major organ failure) throughout
follow-up (before October 31, 2013).
a Two patients had low diffusion capacity of the lung for carbonmonoxide.
bOne patient received the first cyclophosphamide pulse before randomization.
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necessary forpatients’ supportivecareandsafetywereallowed
at the discretion of the investigators. Adherence to European
Group for Blood and Marrow Transplantation guidelines was
recommended.15After2008,guidancewasprovidedonthemoni-
toringofEBV loadbypolymerasechain reactionafterHSCT. In-
vestigatorswereadvisedto initiateprophylactic treatmentwith
angiotensin-convertingenzymeinhibitorsinallpatientsenrolled.
Data Collection and Assessment of Data Quality
Patientswereseenevery3months in the first2years, andyearly
thereafter,forphysicalexamination,fullbloodcellcount,anduri-
nalysisandformeasurementofskinscore,toxicity,andtheHealth
AssessmentQuestionnaireDisability Index (HAQ-DI), fora total
follow-upof7years.Patientsandassessorswerenotblinded.Op-
tions for ethnic originwerepredefined in the case record forms
anddeterminedbyeach investigator. Informationonqualityof
life (36-itemShort FormGeneralHealth Survey [SF-36] andEu-
roQol [EQ-5D])was collected at 3 and 6months and then every
6months in the first 2yearsandannually thereafter.Lung func-
tiontests,echocardiographyormultiple-gatedacquisitionscan,
andelectrocardiographywereperformedyearlyupto7yearsaf-
ter enrollment. Survival and the absence ofmajor organ failure
among patients with follow-up longer than 7 years were ascer-
tained by telephone calls or e-mailswith the investigators.
Collected data were transferred to the study administra-
tionoffice,which stored,managed, andanalyzed thedata.An
independent data and safety monitoring committee moni-
tored efficacy and safety data.
Study End Points
Theprimary endpointwas event-free survival, defined as the
time indays fromrandomizationuntil theoccurrenceofdeath
due to any cause or the development of persistent major or-
ganfailure (heart, lung,kidney),definedas leftventricularejec-
tion fraction less than 30%byechocardiography (ormultiple-
gatedacquisitionscan), restingarterialoxygentension less than
8 kPa (60 mm Hg) and/or resting arterial carbon dioxide ten-
sion greater than 6.7 kPa (50mmHg) without oxygen supply,
or the need for renal replacement therapy. Each event (death
ormajororgan failure)was reviewedandadjudicated inanon-
blindedmanner by the independent data and safetymonitor-
ing committee, which determined whether it was deemed
treatment-related or attributable to disease progression.
Themainsecondaryendpointsofthestudyweretreatment-
relatedmortality, toxicity, andchanges inmRSS (minimally im-
portantdifference,3.2-5.3),17organfunction(heart, lung,kidney),
HAQ-DI (minimally important difference, 0.10-0.14)17, body
weight, SF-36 score, andEQ-5D scorewithin 24months follow-
ingrandomization.Theneedforimmunosuppressivetherapybe-
tween 12 and 24months served as an additional endpoint.
Power Analyses
Wecalculated that 75patientswereneeded ineachgroup,with
a total studyand follow-upperiodof 11 years, includingat least
1-year follow-up of the last patient with an annual event rate
of 9.5% (50 events in total), to detect a hazard ratio of 0.5, in-
dicating that half as many patients in the intervention group
hadexperiencedanevent as comparedwith the control group,
assuming a 5% loss to follow-up after 8 years in both groups
(α = .05 [2-sided]; power = .67 [1-sided]).
Statistical Analysis
Data collectedbyOctober 31, 2013,were included in the analy-
sis, consistent with a 4-year follow-up after the last partici-
pantwasenrolled.Data forpatientswhosurvivedandfor those
surviving event-free were censored at the date of the last fol-
low-up visit. We analyzed all data by intention-to-treat (ITT)
andreport rawestimateswithoutadjustment forbaselinechar-
acteristics. Inaddition,per-protocol sensitivityanalysesof sec-
ondary outcomes were performed.
Primaryanalysescomparedevent-freesurvivalbetweenthe
studygroupsbyconstructingKaplan-Meiersurvivalcurvesbased
onthetimetothefirstevent, ignoringadditional failures,andby
using the log-rank test andaCoxregressionmodel.Because the
survival curves crossed, the treatment × time interaction was
modeledallowingagradualchangeofthehazardofthetransplant
group crossing the hazard of the control group at 0.5 years and
endingupas a constant after 2 years of follow-up.Weanalyzed,
byITT,thetreatmentresponsesinclinicaloutcomevariablessuch
as themRSS,HAQ-DI,visceral involvement,bodyweight, SF-36
score, andEQ-5Dscore inpatients still aliveat 2yearsusingarea
under the time-response curve (AUC).We testedwhether data
weremissingatrandombycomparingbaselinecharacteristicsbe-
tween patients with missing values (cases with missings) and
withoutmissingvalues (complete cases)during the first 2years
in2scenarios: (1) inclusionofpatientswhodiedinthefirst2years
of follow-up and (2) exclusion of nonsurvivors. Some baseline
characteristicswerestatistically significantlydifferentbetween
completecasesandcaseswithmissingswhennonsurvivorswere
includedintheanalysis.Althoughtherewerenostatisticallysig-
nificantdifferencesbetweencompletecasesandcaseswithmiss-
ingswhennonsurvivorswereexcluded,forsomeparametersthe
Pvaluewasslightlygreaterthan.05.Weconcludedthatdatawere
notmissing at random.We therefore used thenearest observa-
tionintimeforpatientswhosurvivedthefirst2yearsorthepoor-
est possible values when data were missing because of death.
Areas under the curve were compared between the treatment
groups by t test.
In apost hoc analysis,weused theBreslow-Day test for ho-
mogeneityofoddsratiostodeterminedifferencesinthetreatment
effectacrosscategoriesforsubgroupsofage(≤45years,>45years),
sex,diseaseduration (<2years,≥2years), smokingstatus (never
smoked, ever smoked), pretrial use of cyclophosphamide, and
baseline bodyweight (≤66.5 kg, >66.5 kg) at 2 years’ follow-up.
Ninety-five percent confidence intervals were computed
where appropriate, with P values less than .05 (2-sided) con-
sidered statistically significant. Binary variables were ana-
lyzed by the Fisher exact test. Statistical analyses were per-
formed using STATA version 12.0 (StataCorp).
Results
Patients and Treatment
FromMarch2001 toOctober2009, 156patientsunderwent ran-
domization in 29 centers (28 in Europe and 1 in Canada). Sev-
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enty-ninepatientswere randomized toHSCTand77were ran-
domized to cyclophosphamide (Figure 1). The number of
individuals screenedandexcludedwasnotavailable forall cen-
ters. Baseline characteristics of the patients were similar be-
tween the 2 groups (Table 1).
Seventy-five patients in each group started treatment. Six
patients did not receive the allocated treatment, whereas 71
(89.8%) and 57 (74.0%) completed treatment in theHSCT and
cyclophosphamide groups, respectively (Figure 1). All 156 pa-
tients were included in the ITT population. The median
Table 1. Baseline Characteristics of Study Patients
Characteristic
No. (%)
All Patients
(N = 156)
HSCT Group
(n = 79)
Control Group
(n = 77)
Age, mean (SD), y 43.8 (11.3) 44.2 (11.1) 43.3 (11.5)
Women 92 (59.0) 43 (54.4) 49 (63.6)
Ethnic origin
White 125 (80.8) 63 (79.7) 62 (80.5)
North African 9 (5.1) 5 (6.3) 4 (5.2)
Asian 6 (3.8) 2 (2.5) 4 (5.2)
Middle Eastern 2 (1.3) 0 2 (2.6)
Othera 14 (9.0) 9 (11.4) 5 (6.5)
Time since diagnosis, mean (SD), y 1.4 (1.3) 1.4 (1.2) 1.5 (1.4)
Duration of skin involvement, mean (SD), y 1.7 (1.3) 1.7 (1.2) 1.7 (1.3)
Major organ involvement
Lung 135 (86.5) 68 (86.1) 67 (87.0)
Kidney 5 (3.2) 3 (3.8) 2 (2.6)
Heart 13 (8.3) 6 (7.6) 7 (9.1)
None 16 (10.3) 8 (10.1) 8 (10.4)
Smoking status
Current 23 (14.7) 10 (12.7) 13 (16.9)
Former 61 (39.1) 31 (39.2) 30 (39.0)
Never 72 (46.2) 38 (48.1) 34 (44.2)
Pretrial use of cyclophosphamide 34 (21.8) 17 (21.5) 17 (22.1)
Weight, mean (SD), kgb 68.6 (14.4) 71.5 (15.2) 65.6 (12.9)
Body mass index, mean (SD)c 23.8 (4.1) 24.7 (4.1) 22.9 (4.0)
Modified Rodnan skin score, mean (SD)d 25.3 (8.0) 24.8 (8.1) 25.8 (7.9)
Creatinine clearance, mean (SD), mL/mine 76.7 (25.9) 76.8 (26.1) 76.5 (26.0)
Cardiac
Abnormal electrocardiogramf 24 (16.0) 10 (13.2) [n = 76] 14 (18.9) [n = 74]
Pericardial effusion 12 (7.8)g 4 (5.1) [n = 78] 8 (10.5) [n = 76]
LVEF (%) by cardiac echocardiography,
mean (SD)
65.6 (7.6) 65.6 (7.5) [n = 70] 65.7 (7.8) [n = 67]
Lung
Abnormal thoracic computed
tomographyh
125 (83.3) 66 (86.8) [n = 76] 59 (79.7) [n = 74]
Forced vital capacity, mean (SD), %
predicted
81.4 (18.4) 81.7 (19.3) 81.1 (17.6)
Total lung capacity, mean (SD). %
predicted
80.7 (16.6) 81.0 (17.1) [n = 75] 80.5 (16.2) [n = 75]
Residual volume, mean (SD), % predicted 90.1 (30.3) 90.4 (30.1) [n = 71] 89.9 (30.6) [n = 71]
DLCO mean (SD), % predicted 58.5 (14.1) 59.3 (14.3) [n = 79] 57.7 (14.0) [n = 76]
Pulmonary arterial hypertensioni 10 (6.6) 4 (5.2) [n = 77] 6 (8.1) [n = 74]
HAQ-DI, mean (SD)j 1.35 (0.80) 1.25 (0.74) [n = 68] 1.44 (0.84) [n = 73]
SF-36, mean (SD)k [n = 59] [n = 66]
Physical component 32.2 (10.0) 32.2 (10.4) 32.2 (9.6)
Mental component 42.0 (11.4) 41.2 (10.7) 42.6 (12.0)
EQ-5D, mean (SD)l [n = 65] [n = 73]
Index-based utility score 0.47 (0.32) 0.46 (0.32) 0.47 (0.32)
VAS score 51.9 (21.5) 53.4 (22.1) 50.7 (21.1)
Antinuclear antibody positive 150 (95.1) 75 (94.9) 75 (97.4)
Antitopoisomerase antibody positivem 114 (73.5) 52 (66.7) 62 (80.5)
Abbreviations:DLCO,diffusion capac-
ity of the lung for carbonmonoxide;
HAQ-DI, health assessmentquestion-
naire disability index;HSCT, hemato-
poietic stemcell transplantation; LVEF,
left ventricular ejection fraction; SF-36,
36-ItemShort FormGeneralHealth
Survey;VAS, visual analog scale.
a Included theWest Indies (8
patients), South America (4
patients), andmixed (2 patients).
bWeight differed significantly
between groups (P = .01).
c Calculated as weight in kilograms
divided by height in meters
squared. Index differed significantly
between groups (P = .007).
d Scores can range from0-51, with
higher scores indicating more
severe skin thickening.
e Estimated using the Cockcroft-Gault
formula.
f Defined as presence of atrial or
ventricular rhythm disturbances
such as recurrent episodes of atrial
fibrillation or flutter, recurrent atrial
paroxysmal tachycardia or
ventricular tachycardia, second- or
third-degree AV block, or diffuse
microvoltage or repolarisation
abnormalities related to pericardial
effusion, whereas
non–scleroderma-related causes
were excluded.
g All 12 patients hadmoderate
pericardial effusion as assessed by
echocardiography.
hDefined as interstitial lung disease
on HR-CT scan, whereas other
causes of clinically relevant
obstructive disease and
emphysemawere excluded
i Defined as a mean pulmonary artery
pressure greater than 25 mm Hg and
less than 50 mm Hg, measured by
cardiacechocardiographyorcatheter-
izationof the right sideof theheart.
j Scores can range from1 to3,with
lower scores indicating less disability.
k Scores can range from0-100, with
higher scores indicating better
health status.
l Typically interpreted along a
continuum in which 1 represents
best possible health and 0
represents dead. VAS scores range
from0 (worst imaginable health
state) to 100 (best imaginable
health state).
mData were available for 155 patients.
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follow-upof event-free survival of the ITTpopulationswas5.8
years (interquartile range, 4.1-7.8). Treatment-specific details
are provided in eTable 1A and eTable 1B in the Supplement.
Primary End Point
A total of 53 events occurred during the study: 22 in the HSCT
group(19deathsand3 irreversibleorganfailures;8patientsdied
of treatment-relatedcauses inthefirstyear,9ofdiseaseprogres-
sion, 1of cerebrovasculardisease, 1ofmalignancy)and31 in the
controlgroup(23deathsand8irreversibleorganfailures[7ofthese
patientsdied later]; 19patientsdiedofdiseaseprogression,4of
cardiovasculardisease,5ofmalignancy,2ofothercauses)(eTable
2A and eTable 2B in the Supplement).
Thehazardratiosforevent-freesurvivalandoverall survival
were time-varying (P = .04andP = .03, respectively) (Figure2).
Patients treatedwithHSCTexperiencedmoreevents in the first
year but had better long-term event-free survival than those
treatedwithcyclophosphamide.Duringthefirstyear, therewere
13 events (16.5%) in theHSCTgroupvs 8 (10.4%) in the control
group (relative risk [RR], 1.59 [ 95% CI, 0.7-4.4]). After 2 years
of follow-up therewere 14 events (17.7%) in theHSCTgroupvs
14 (18.2%) in the control group (RR, 0.97 [95%CI, 0.5-2.0]). Af-
ter 4 years of follow-up there were 15 events (19.0%) in HSCT
groupvs 20 (26.0%) in the control group (RR,0.73 [95%CI, 0.4-
1.3]).Corresponding time-varyinghazard ratios for theprimary
outcomeofdeathormajororganfailurewere0.52 (95%CI,0.28-
0.96; P = .04) at 1-year follow-up; 0.35 (95% CI, 0.16-0.74;
P = .006) at 2-year follow-up; and 0.34 (95%CI, 0.16-0.74; P =
.006)at4-yearfollow-up.PatientsintheHCSTgroupexperienced
highermortality in the first yearbuthadbetter long-termover-
all survival than those treatedwithcyclophosphamide.During
year1 therewere11deaths (13.9%, including8treatment-related
deaths) in theHSCT group vs 7 (9.1%, none treatment-related)
in the control group (RR, 1.53 [95%CI, 0.4-5.4]). After year 2 of
follow-up therewere 12deaths (15.2%) in theHSCTgroupvs 13
(16.9%) in the control group (RR, 0.90 [95%CI, 0.4-1.8]). After
4 years of follow-up there were 13 deaths (16.5%) in the HSCT
groupvs20 (26.0%) in thecontrol group (RR,0.64 [95%CI,0.3-
1.1]). Corresponding time-varyingHRs formortalitywere0.48
(95%CI,0.25-0.91;P = .02)at1-year follow-up,0.29(95%CI,0.13-
0.65;P = .002)at2-year follow-up,and0.29(95%CI,0.13 to0.64;
P = .002) at4-year follow-up.The lowerhazard ratiosvshigher
relativerisks forevent-freesurvivalandoverall survivalat 1year
for the HSCT vs control group reflect a change in event rate in
the HSCT group, because themajority of events are being ob-
served inthe first6monthsbut theevent rate in theHSCTgroup
isalreadyfavorableat1yearascomparedwiththerelativelycon-
stant event rate in the control group.
No center effect was found, with 5 of 8 treatment-related
deaths observed in 3 of the 4 most active autoimmune dis-
ease transplant centers in Europe.
Secondary End Points
TheanalysisoftheAUCshowedsignificantdifferencesinthesec-
ondary outcomemeasures. Mean change from baseline until 2
years’ follow-up in mRSS was significantly better in the HSCT
group(−19.9)thaninthecontrolgroup(−8.8)(difference,11.1[95%
CI,7.3 to15.0];P < .001),asweremeanchanges inforcedvitalca-
pacity (6.3%predictedvs−2.8%predicted;difference,−9.1 [95%
CI,−14.7 to−2.5];P = .004), total lungcapacity (5.1%predictedvs
−1.3%predicted;difference,−6.4[95%CI,−11.9to−0.9];P = .02),
HAQ-DI (−0.58vs−0.19;difference,0.39 [95%CI,0.0.51 to0.73];
P = .02), thephysical component score of the SF-36 (10.1 vs 4.0;
difference, −6.1 [95%CI, −10.9 to −1.4]; P = .03), and the EQ-5D
index–basedutilityscore (0.31vs0.03;difference,−0.29[95%CI,
−0.45to−0.12];P < .001)whereasmeanchangeincreatinineclear-
Figure 2. Event-Free andOverall Survival During 10-Year Follow-up
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Hazard ratios (HRs) and 95% CIs were calculated by Cox regression. Hazard
ratios were time-varying. The hazard (slope of the survival curve) in the
hematopoietic stem cell transplantation (HSCT) group is initially high because of
treatment-relatedmortality but gradually improves. At 1-year follow-up, the HR
already favors the HSCT group, which leads to the crossing of the survival
curves at 2 years’ follow-up. A, Three-month follow-up: HR, 2.01 (95% CI,
0.74-5.49); P = .17; 6-month follow-up: HR, 1.35 (95% CI, 0.62-2.96); P = .45;
1-year follow-up: HR, 0.52 (95% CI, 0.28-0.96); P = .04; 2-year follow-up: HR,
0.35 (95% CI, 0.16-0.74); P = .006; 3- through 10-year follow-up: HR, 0.34
(95% CI, 0.16-0.74); P = .006. B, Three-month follow-up: HR, 2.40 (95% CI,
0.75-7.67); P = .14; 6-month follow-up: HR, 1.50 (95% CI, 0.61-3.68); P = .38;
1-year follow-up: HR, 0.48 (95% CI, 0.25-0.91; P = .02; 2-year follow-up: HR,
0.29 (95% CI, 0.13-0.65); P = .002; 3- through 10-year follow-up: HR, 0.29
(95% CI, 0.13-0.64); P = .002.
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ance (mL/min)wassignificantlyworse intheHSCTgroup(−12.1)
thaninthecontrolgroup(−1.2) (difference,10.9[95%CI,1.5-20.3];
P = .02)(Table2).Nostatisticallysignificantdifferencesinleftven-
tricularejection fraction, residualvolume,andthediffusionca-
pacityof the lung for carbonmonoxidewereobservedbetween
the 2 groups.
These resultswere also confirmed by the sensitivity analy-
sis,which showedsimilarpoint estimatesof theeffect size (dif-
ferences inmeanAUC) forall of thesecondaryendpoints;how-
ever, losing statistical significance for someendpointsbecause
ofthesmallernumberofpatientsintheanalysisorusingthepoor-
est possible values (based on observed data in the whole trial
population)whendataweremissingbecauseofdeath(forcedvi-
tal capacity, total lung capacity,HAQ-DI, and thephysical com-
ponentscoreoftheSF-36)(eTable3intheSupplement).Inthepost
hocsubgroupanalysis, therewerenostatisticallysignificantdif-
ferences intheoddsratiosof thetreatmenteffectontheprimary
endpointacrosscategoriesofage, sex,diseaseduration,pretrial
cyclophosphamideuse,andbaselineweightat2years’ follow-up
(P ≥ .26).However,therewassignificantheterogeneityinthetreat-
menteffectacrosscategoriesofsmokingstatus(P = .02) (eFigure
1 intheSupplement).Eightpatients inthecontrolgroupreceived
rescueHSCTafter2years,1ofwhomdiedfromtreatment-related
acutemyeloid leukemia despite allogeneicHSCT. Twopatients
intheHSCTgroupreceivedrescueintravenouscyclophosphamide
therapy after 2 years. A smaller number of patients in theHSCT
groupascomparedwiththecontrolgroupreceivedimmunosup-
pressivemedicationbetween12and24months (15 [22.4%]vs28
[43.8%],P = .02) (eTable 4 in the Supplement).
Eightdeaths(10.1%ofITTpopulation), including1duringmo-
bilization and 1 during conditioning in the HSCT group, were
deemedtreatment-relatedby the independentdatamonitoring
committee vs none in the control group (P = .007). Causes of
treatment-relateddeathsincludedEBV,lymphoma,heartfailure,
myocardial infarction, andacute respiratorydistress syndrome
(eTable5 in theSupplement). Sevenof8patientswhodiedfrom
treatment-related causeswere current or former smokers. Five
(2intheHSCTgroupand3inthecontrolgroup)of10patientswith
PAHdiedbefore thecutoffdate.Grade3or4adverseeventsoc-
curred in51patients (62.9%) intheHSCTgroupand30(37.0%) in
the control group (P = .002) (Table 3). Viral infections were de-
tected in22patients (27.8%) in theHSCTgroupvs 1 (1.3%) in the
controlgroup(P < .001).Except for 1patient in thecontrolgroup
withaprimaryherpessimplexvirus infection,all infectionswith
cytomegalovirus (9), EBV (6), herpes simplexvirus (11), varicel-
la zoster virus (3), andhepatitisBvirus (1) occurred in theHSCT
group (eTable6 in theSupplement). Threepatients in theHSCT
grouphad cytomegalovirus/herpes simplexvirus co-infection.
Twoof the patientswith EBVdevelopedEBV-positive lympho-
proliferativedisorder: 1wassuccessfully treatedwithrituximab,
theotherpresentedwith fulminantdiseasewith fataloutcome.
FivepatientswithCMVinfectionreceivedoralor intravenousan-
tiviral treatment.
Discussion
This phase 3 study demonstrated that autologous HSCT using
high-dose cyclophosphamide, rbATG, and reinfusion of CD34-
selectedcellswasassociatedwithearlytreatment-relateddeaths
but better long-term event-free survival (the primary outcome
measure)andbetteroverallsurvivalatamedianof5.8(interquar-
Table 2. Treatment Responses in Clinical Outcome Variables, Change in the Area Under the Time Response Curve FromBaseline to 2 Years’ Follow-up
Variable
AUC, Mean (SD)
Difference (95% CI) P Value
HSCT Group
(n = 67)a
Control Group
(n = 64)a
Weight, kg –0.7 (9.5) –0.8 (9.6) –0.2 (–3.5 to 3.1) .91
Modified Rodnan skin score –19.9 (10.2) –8.8 (12.0) 11.1 (7.3 to 15.0) <.001
Creatinine clearance, mL/minb –12.1 (29.7) –1.2 (24.1) 10.9 (1.5 to 20.3) .02
LVEF, % by cardiac echocardiography –2.2 (14.7) –1.9 (13.8) 0.3 (–4.7 to 5.2) .91
Forced vital capacity, % predicted 6.3 (18.3) –2.8 (17.2) –9.1 (–14.7 to –2.5) .004
Total lung capacity, % predicted 5.1 (17.5) –1.3 (13.9) –6.4 (–11.9 to –0.9) .02
Residual volume, % predicted –4.8 (33.7) –2.1 (26.9) 2.7 (–7.9 to 13.2) .62
DLCO, % predicted –4.7 (13.7) –4.1 (17.6) 0.6 (–4.9 to 6.0) .84
HAQ-DI –0.58 (1.14) –0.19 (0.79) 0.39 (0.51 to 0.73) .02
SF-36 score
Physical component 10.1 (15.8) 4.0 (11.2) –6.1 (–10.9 to –1.4) .01
Mental component 3.1 (16.0) 3.4 (17.1) 0.3 (–5.41 to 6.07) .91
EQ-5D
Index-based utility score 0.31 (0.50) 0.03 (0.44) –0.29 (–0.45 to –0.12) <.001
VAS score 16.9 (44.5) 10.2 (39.7) –6.7 (–21.33 to 7.87) .36
Abbreviations: AUC, areaunder the curve;DLCO,diffusion capacity of the lung for
carbonmonoxide;HAQ-DI,HealthAssessmentQuestionnaireDisability Index;
HSCT, hematopoietic stemcell transplantation; LVEF, left ventricular ejection frac-
tion; SF-36, 36-itemShort FormGeneralHealth Survey;VAS, visual analog scale.
a Sixty-sevenpatients in theHSCTgroupand64patients in the control groupwere
still alive at 2 years after randomization andwere included in the analysis per the
intention-to-treat principle. If a clinical outcomevaluewasmissing, thenearest
available observation (in time, previousor next observation)wasused to impute
themissing value. Increase in themodifiedRodnan skin score andHAQ-DI indi-
catesworsening. Increase in all other variables indicates improvement.
b Two patients in the HSCT group and 1 patient in the control group, all with
renal failure, were excluded from the analysis. Creatinine clearance was
estimated by using the Cockroft-Gault formula.
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tile range, 4.1-7.8) years’ follow-up comparedwith intravenous
pulsecyclophosphamideforpatientswithdiffusecutaneoussys-
temicsclerosis.The long-termsurvivalbenefitofHSCTwaspar-
ticularly striking in thosewhohadnever smoked. Smokinghas
been shown tobe associatedwithmore severe systemic sclero-
sisandhasbeenshowntoinfluencetheoutcomeafterallogeneic
HSCTinmalignantdiseases, inpart througheffectsonpretrans-
plant lung function.18-20
HSCTwasalsomoreeffective than intravenouspulsecyclo-
phosphamide for theoutcomesof skin score, functional ability,
quality of life, and lung function, consistent with previous
studies.4-11HSCTwasassociatedwithmoregrade3and4adverse
events includingrespiratorydistress,possiblyduetorbATGand
10.1%treatment-relatedmortality,viral infections,andamodest
decrease in creatinine clearance. The lattermaybe attributable
to thenephrotoxiceffectsofmedicationusedduringcondition-
ing (glucocorticoids, cyclophosphamide, rbATG). Of note,
treatment-relatedmortalitydecreasedfrom17%inthefirstphase
1-2multicenterstudyto6%to8.7%in2registryanalysesofHSCT
inautoimmunediseases that also reportedevidenceof a center
effect.4,9,21,22Wedidnot findacentereffect,but7of8treatment-
related deaths occurred in current or former smokers. A recent
retrospectivestudysuggestedthatcatheterizationoftherightside
of theheartwithfluidchallengeandcardiacmagnetic resonance
imaging may identify patients at risk of treatment-related
mortality.9Another recent studydemonstrated theclinicalutil-
ity of left heart catheterization in addition to catheterization of
theright sideof theheartwith fluidchallengebyshowingahigh
prevalenceof leftventriculardysfunction inpatients suspected
ofhavingPAH.23Threeof8treatment-relateddeathsinourstudy
wereattributedtoaprimarycardiaccause.Tobalancethepoten-
tial risksofHSCT,our trialdeliberately targetedpatientswithse-
veresystemicsclerosis, including10patientswithPAH,5ofwhom
died.Akeyproblem in themanagementof systemic sclerosis is
to identify patients at risk of disease progression and strike the
rightbalancebetweenthe long-termbenefits andupfront risks,
including treatment-relatedmortalityofan intensive treatment
modalitysuchasHSCTasopposedtostandardimmunosuppres-
sioncurrently recommended.24Diseasecharacteristics recently
associatedwithprematuremortalitymaybeusedto identifypa-
tients suitable forHSCT.25,26
Ourstudyhaslimitations.First,wideconfidenceintervalsfor
somesecondaryoutcomemeasuresareindicativeoflesscertainty
about results for theseoutcomes.Second, theunblindedassess-
mentsmayhave influencedour results.Third, thedrop-out rate
in the cyclophosphamide groupwas greater than 20%because
ofdeath,majororgan failure, adverseevents,ornonadherence.
Conclusions
Among patients with early diffuse cutaneous systemic scle-
rosis,HSCTwasmoreeffective thanmonthly intravenouspulse
cyclophosphamide and, despite an early treatment-related
mortality rate of 10.1% and an increase in serious adverse
events, conferred a long-term survival benefit.
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Table 3. Grade 3 and 4 Adverse Events in the First 2 Years of Follow-up
Adverse Eventa
Patients, No. (%)
P Valueb
HSCT Group
(n = 79)
Control Group
(n = 77)
Grade 3 or 4 adverse event, severe or life-threatening 51 (62.9) 30 (37.0) .002
Any grade 3 adverse event 38 (48.1) 20 (26.0) .005
Any grade 4 adverse event 29 (36.7) 21 (27.3) .23
Adverse event with a fatal outcome 12 (15.2) 13 (16.9) .83
Adverse event of grade 3-4
Respiratory 15 (19.0) 6 (7.8) .06
Cardiovascular 13 (16.5) 8 (10.4) .35
Gastrointestinal 10 (12.7) 11 (14.3) .82
Hematologic 10 (12.7) 1 (1.3) .009
Renal 8 (10.1) 4 (5.2) .37
Infection 8 (10.1) 4 (5.2) .37
Neurologic 5 (6.3) 1 (1.3) .21
Fever 5 (6.3) 0 .06
Musculoskeletal 3 (3.8) 2 (2.6) >.99
Cancer 0 3 (3.9) .12
Allergy/hypersensitivity 3 (3.8) 0 .24
Urogenital 0 2 (2.6) .24
Sarcoidosis 1 (1.3) 0 >.99
Flushing 0 1 (1.3) .49
Psychiatric 0 1 (1.3) .49
Abbreviation: HSCT, hematopoietic
stem cell transplantation.
a All grade 3 and 4 (severe and
life-threatening) adverse event data
are included. Severity for each
adverse event, including any
laboratory abnormality, was
determined by using theWorld
Health Organization Common
Toxicity Parameters, wherever
possible. In those cases in which
these criteria did not apply, a severe
adverse event was defined as one
causing inability to perform normal
daily activities, and a
life-threatening event as one posing
immediate risk of death from the
reaction as it occurred.
bP values were calculated by Fisher
exact test.
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